The RSK2 kinase is a downstream effector of the Ras/Raf/MEK/ERK pathway that is aberrantly active in a range of cancer types and has been recognized an anticancer target. The inhibition of RSK2 kinase activity would disrupt multiple pro-cancer processes; however. there are few RSK2 inhibitors. The data have been obtained for a series of pteridinone-. https://ashleyshomestores.shop/product-category/king-hp-foundation/